3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Conditions
Lung Neoplasms
2
Head and Neck Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Uterine Cervical Neoplasms
1
Urologic Neoplasms
1
Thoracic Diseases
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Skin Neoplasms
1
Neoplasm Metastasis
1
Mesothelioma, Malignant
1
Lymphoma
1
Liver Neoplasms
1
Leukemia
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Clear-cell metastatic renal cell carcinoma
1
Carcinosarcoma
1
Carcinoma, Renal Cell
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Interventions
pembrolizumab
63
Nivolumab
44
atezolizumab
14
Docetaxel
10
Cyclophosphamide
10
Paclitaxel
9
Magnetic Resonance Spectroscopy
9
Ipilimumab
9
avelumab
8
Specimen Handling
8
durvalumab
7
Radiosurgery
7
Cetuximab
7
spartalizumab
6
Radiotherapy
6
Immune Checkpoint Inhibitors
6
Interleukin-2
5
Carboplatin
5
fludarabine
4
cabozantinib
4
Trastuzumab
4
Sunitinib
4
Psychiatric Rehabilitation
4
Pemetrexed
4
Oxaliplatin
4
Fluorodeoxyglucose F18
4
Everolimus
4
Cisplatin
4
Capecitabine
4
Bevacizumab
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Renal Cell
×
Tissue Banks
×
Thoracic
×
Clear all
NCT06349642
2026-03-12
ELEPHAS-04
Mayo Clinic
Recruiting
324 enrolled